Location Choices of the Pharmaceutical Industry in Europe after 1992

Frances Ruane () and Xiaoheng Zhang

The Institute for International Integration Studies Discussion Paper Series from IIIS

Abstract: Differences in regulations,technical standards and national medical cultures across EU member states created a highly segmented pharmaceutical market in Europe prior to the implementation of the Single Market Programme. The subsequent reduction in non-tariff barriers to trade would be expected to have an impact on where pharmaceutical multinationals locate production within the EU.Using discrete choice models, we study separately the determinants of multinational location choices in terms of expanded production at existing facilities and location of start-up firms.Our results support the findings of models which predict reduced rather than increased agglomeration in the face of trade-cost reductions.

Date: 2007-04-17
New Economics Papers: this item is included in nep-dcm, nep-geo and nep-hea
Note: Length:
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (68)

Downloads: (external link)
https://www.tcd.ie/triss/assets/PDFs/iiis/iiisdp220.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:iis:dispap:iiisdp220

Access Statistics for this paper

More papers in The Institute for International Integration Studies Discussion Paper Series from IIIS 01. Contact information at EDIRC.
Bibliographic data for series maintained by Maeve ().